DBV Technologies Outlines Regulatory Path For Viaskin Peanut Allergy Patch For Kids Below 3 Years

  • DBV Technologies DBVT received written responses from the FDA on the regulatory path for the investigational Viaskin Peanut 250 μg patch (DBV712) in toddlers ages 1 – 3 years old with a confirmed peanut allergy.
  • In the written responses received, the agency confirmed that the Company's Phase 3 EPITOPE study met the pre-specified criteria for success for the primary endpoint. 
  • The FDA did not request an additional efficacy study to support a future BLA but requires that DBV conduct an additional safety study in 1 – 3-year-olds using the original Viaskin Peanut patch to augment the safety data collected from the Phase 3 EPITOPE study. 
  • The new safety study intends to bring the safety database in 1–3-year-olds close to 600 patients on active treatment, which is consistent with the FDA's position supporting the company's dossier in 4–7-year-olds. 
  • The safety study will not require a food challenge for study participation.
  • DBV plans to submit a proposed safety study protocol to the FDA by the end of Q2 2023.
  • Viaskin Peanut in 1 – 3-year-olds (original patch) and Viaskin Peanut in 4 – 7-year-olds (modified patch) will continue as separate product candidates with independent clinical and regulatory paths.
  • The company expects cash and cash equivalents of $192.3 million as of 31 March.
  • Price Action: DBVT shares are down 3.66% at $1.58 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareSmall CapFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!